These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21298745)

  • 1. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2011 Apr; 56(4):595-603. PubMed ID: 21298745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.
    Houghton PJ; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wu J; Smith MA
    Pediatr Blood Cancer; 2010 Jul; 54(7):921-6. PubMed ID: 20166202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
    Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
    Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1190-7. PubMed ID: 18260118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.
    Houghton PJ; Kurmasheva RT; Lyalin D; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2014 Nov; 61(11):1972-9. PubMed ID: 25131802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.
    Houghton PJ; Gorlick R; Kolb EA; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Phelps D; Maris JM; Billups C; Smith MA
    Pediatr Blood Cancer; 2012 Feb; 58(2):191-9. PubMed ID: 21337679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
    Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
    Keir ST; Maris JM; Lock R; Kolb EA; Gorlick R; Carol H; Morton CL; Reynolds CP; Kang MH; Watkins A; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2010 Dec; 55(6):1126-33. PubMed ID: 20672370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.
    Smith MA; Maris JM; Lock R; Kolb EA; Gorlick R; Keir ST; Carol H; Morton CL; Reynolds CP; Kang MH; Houghton PJ
    Pediatr Blood Cancer; 2011 Aug; 57(2):268-74. PubMed ID: 21360650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
    Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27650817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.
    Carol H; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ; Lock RB
    Pediatr Blood Cancer; 2010 Dec; 55(7):1329-37. PubMed ID: 20740623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.
    Carol H; Reynolds CP; Kang MH; Keir ST; Maris JM; Gorlick R; Kolb EA; Billups CA; Geier B; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB
    Pediatr Blood Cancer; 2013 Apr; 60(4):633-41. PubMed ID: 22753001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial testing of cisplatin by the pediatric preclinical testing program.
    Tajbakhsh M; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB
    Pediatr Blood Cancer; 2008 May; 50(5):992-1000. PubMed ID: 17554786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.
    Lock RB; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gorlick R; Kolb EA; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2012 Jun; 58(6):916-23. PubMed ID: 21584937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
    Reynolds CP; Kang MH; Carol H; Lock R; Gorlick R; Kolb EA; Kurmasheva RT; Keir ST; Maris JM; Billups CA; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 May; 60(5):791-8. PubMed ID: 23002019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
    Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 Aug; 60(8):1325-32. PubMed ID: 23553917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kolb EA; Gorlick R; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Apr; 50(4):799-805. PubMed ID: 17635004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
    Carboni JM; Wittman M; Yang Z; Lee F; Greer A; Hurlburt W; Hillerman S; Cao C; Cantor GH; Dell-John J; Chen C; Discenza L; Menard K; Li A; Trainor G; Vyas D; Kramer R; Attar RM; Gottardis MM
    Mol Cancer Ther; 2009 Dec; 8(12):3341-9. PubMed ID: 19996272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.